Cincinnati CRS – ACTG Network

Location	University of Cincinnati University Hospital Holmes Division, ML 405 Eden & Albert Sabin Way (IDC) Cincinnati OH 45267-0405
CRS Coordinator	Sharon Kohrs kohrssd@ucmail.uc.edu 513-584-6383
CRS Leader	Carl Fichtenbaum carl.fichtenbaum@uc.edu 513-584-6361
Studies	A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5332: REPRIEVE Trial A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT) A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP) A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) ACTG A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)